Phase I/IIa Trial Evaluating Safety of LOAd703, an Armed Oncolytic Adenovirus for Pancreatic Cancer
Summary
The purpose of this phase I/II study is to evaluate the safety and efficacy of LOAd703 in combination with gemcitabine and nab-paclitaxel with or without Atezolizumab in patients with pancreatic cancer.
General Information
NCT#: NCT02705196
Study ID: LOKON001
Trial Phase: Phase I/II
Trial Sponsor: Lokon Pharma AB
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, LOAd703 Injection, Atezolizumab